Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)

Table 4 Literature data of chemotherapy agents and TT for advanced TT

Chemotherapy agent	Patients number	Best response	PFS	References
Vinorelbine-Cyclophosphamide	2	2 PR	4 and 15 months	Ferrari et al. [18]
Irinotecan	8	4 SD, 4 PD	Unknown	Bisogno et al. [19]
Trabectedine	2	2 SD	4 months	Frezza et al. [21]
TT agent
Imatinib	7	1 PR, 4 PD, 2 NA	1 month	Chao et al. [22]
Sunitinib	8	2 PR, 3 SD, 3 PD	2.6 months	Italiano et al. [23]
Pazopanib^c	9	2 PR, 5 SD, 2 PD, CBR^a 78%	9.2 months	Frezza et al. [24]
Temsirolimus	1	SD	10 months	Thijs et al. [33]
Ganitumab	16	1 PR, 10 SD, 4 PD, CBR^b 25%	19 months	Tap et al. [30]

PR partial response, SD stable disease, PD progressive disease, NA non assessable, CBR clinical benefit rate (PR + SD >12 weeks^a, 24 weeks^b)
^cRetrospective analysis from data comprising three DSRCT patients treated within the EORTC phase II study 62043, three in the EORTC phase III study 62072 (PALETTE), along with three patients treated in the UK on the subsequent pazopanib named patient program

ISSN: 2045-3329